CA3233135A1 - Peptides with multivalent effects - Google Patents

Peptides with multivalent effects Download PDF

Info

Publication number
CA3233135A1
CA3233135A1 CA3233135A CA3233135A CA3233135A1 CA 3233135 A1 CA3233135 A1 CA 3233135A1 CA 3233135 A CA3233135 A CA 3233135A CA 3233135 A CA3233135 A CA 3233135A CA 3233135 A1 CA3233135 A1 CA 3233135A1
Authority
CA
Canada
Prior art keywords
amino acids
peptide
seq
peptides
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233135A
Other languages
English (en)
French (fr)
Inventor
Artur Schmidtchen
Ganna PETRUK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IN2CURE AB
Original Assignee
IN2CURE AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IN2CURE AB filed Critical IN2CURE AB
Publication of CA3233135A1 publication Critical patent/CA3233135A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3233135A 2021-10-22 2022-10-21 Peptides with multivalent effects Pending CA3233135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204274.1 2021-10-22
EP21204274 2021-10-22
PCT/EP2022/079429 WO2023067167A1 (en) 2021-10-22 2022-10-21 Peptides with multivalent effects

Publications (1)

Publication Number Publication Date
CA3233135A1 true CA3233135A1 (en) 2023-04-27

Family

ID=78592450

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233135A Pending CA3233135A1 (en) 2021-10-22 2022-10-21 Peptides with multivalent effects

Country Status (7)

Country Link
US (1) US20250313820A1 (enExample)
EP (1) EP4419664A1 (enExample)
JP (1) JP2024539138A (enExample)
CN (1) CN118202043A (enExample)
AU (1) AU2022369065A1 (enExample)
CA (1) CA3233135A1 (enExample)
WO (1) WO2023067167A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024223868A1 (en) * 2023-04-26 2024-10-31 In2Cure Ab Peptides with multivalent effects for topical use
WO2025051955A1 (en) 2023-09-06 2025-03-13 In2Cure Ab Materials with anti-inflammatory and/or anti-microbial properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1987056B1 (en) * 2006-02-10 2012-07-25 Dermagen AB Novel antimicrobial peptides and use thereof
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
AU2018304230A1 (en) 2017-07-19 2020-02-06 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
JP7785001B2 (ja) * 2019-12-18 2025-12-12 イントゥーキュア エービー トロンビン由来ペプチドを含む組成物およびその使用

Also Published As

Publication number Publication date
US20250313820A1 (en) 2025-10-09
JP2024539138A (ja) 2024-10-28
AU2022369065A1 (en) 2024-04-11
WO2023067167A1 (en) 2023-04-27
CN118202043A (zh) 2024-06-14
EP4419664A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
Wei et al. Structure and function of a potent lipopolysaccharide-binding antimicrobial and anti-inflammatory peptide
KR102137941B1 (ko) 항균 펩티드
US8735353B2 (en) Polypeptides and uses thereof
RU2468033C2 (ru) Антибактериальные пептиды
Panjla et al. Short peptides and their mimetics as potent antibacterial agents and antibiotic adjuvants
US20250313820A1 (en) Peptides with multivalent effects
Niu et al. Dual-mechanism glycolipidpeptide with high antimicrobial activity, immunomodulatory activity, and potential application for combined antibacterial therapy
Li et al. Novel β-hairpin antimicrobial peptide containing the β-turn sequence of-NG-and the tryptophan zippers facilitate self-assembly into nanofibers, exhibiting excellent antimicrobial performance
Cárdenas-Martínez et al. Effects of substituting arginine by lysine in bovine lactoferricin derived peptides: pursuing production lower costs, lower hemolysis, and sustained antimicrobial activity
Li et al. Improving selectivity, proteolytic stability, and antitumor activity of Hymenochirin-1B: A novel glycosylated staple strategy
WO2025208807A1 (zh) 一种抗菌肽Thanatin衍生肽及其医药用途
WO2022171098A1 (zh) 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
Shang et al. Engineered peptides harboring cation motifs against multidrug-resistant bacteria
PANDEY et al. The fish venom toxins: natural source of pharmaceuticals and therapeutic agents “Pharmaceutical and therapeutic uses of fish venom toxins
JP2023545740A (ja) 長期活性ＤＮａｓｅ
CN108752433B (zh) 抗微生物肽cramp及其环肽在制备清除细菌生物膜的药物中的应用
WO2019085926A1 (zh) 多黏菌素类似物及其制备方法
WO2008104777A2 (en) Peptide
CN115746097A (zh) 抗菌肽as-12w及其制备方法和用途
Porta et al. Myotoxin a, crotamine and defensin homologs in reptile venoms
CN106674329A (zh) 具备抗微生物、抗癌/促进伤口愈合活性的肽及其用途
US20250101062A1 (en) Antimicrobial peptides
TWI909652B (zh) 具有ｖｅｇｆｒ－２促效劑活性的肽複合物
CN119529055B (zh) 糖基化双环订书肽及其应用
CN117886893B (zh) 一种基于短杆菌肽s衍生设计的抗菌肽及其制备方法与应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241016

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241025

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003